Liraglutide vs Survodutide
A side-by-side research comparison of Liraglutide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Liraglutide | Survodutide |
|---|---|---|
| Full name | Liraglutide (GLP-1 Receptor Agonist / Saxenda) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 3,751 Da | 4,500 Da (approximate) |
| Half-life | 13 hours | 5-7 days |
| Bioavailability | ~55% (subcutaneous) | High (SubQ) |
| Typical dose | 0.6-3.0 mg | 0.6-6.0 mg |
| Frequency | Once daily | Once weekly |
| Route | Subcutaneous | Subcutaneous |
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.